Tonghe Pharmaceutical Co., Ltd.

Legal Opinion from Shanghai Tongli Law Firm on the 2025 Annual Shareholders' Meeting of Jiangxi Tonghe Pharmaceutical Co., Ltd.

Announcement of Resolutions from the 2025 Annual Shareholders' Meeting

Announcement on Obtaining Drug Registration Certificate

Sponsorship Summary Report for Jiangxi Tonghe Pharmaceutical Co., Ltd. Issuing Shares to Specific Objects by China Merchants Securities Co., Ltd.

Tracking Report for Jiangxi Tonghe Pharmaceutical Co., Ltd. in 2025 by China Merchants Securities Co., Ltd.

Announcement on the company's raw material drug obtaining FDA registration approval letter

Announcement on Participation in the Jiangxi Region Listed Companies 2026 Investor Online Collective Reception Day Activities

Announcement on holding the 2025 annual online performance briefing

Announcement on Establishing a Temporary Special Account for Raised Funds and Signing a Tripartite Supervision Agreement

2025 Annual Financial Settlement Report

Announcement on Using Part of Idle Self-owned Funds for Cash Management

Zhongshan Securities Co., Ltd. Verification Opinion on Jiangxi Tonghe Pharmaceutical Co., Ltd. 2025 Fundraising Fund Storage and Usage

Zhongshan Securities Co., Ltd. Verification Opinion on Jiangxi Tonghe Pharmaceutical Co., Ltd. Using Part of Idle Self-owned Funds for Cash Management

Announcement on the Proposed Reappointment of Accounting Firm

Independent Director 2025 Annual Work Report (Li Guoping)

Independent Director 2025 Annual Work Report (Peng Xin)

Independent Director 2025 Annual Work Report (Wan Hong)

Zhongshan Securities Co., Ltd. Verification Opinion on Jiangxi Tonghe Pharmaceutical Co., Ltd. 2025 Internal Control Self-Evaluation Report

2025 Internal Control Audit Report

Self-Evaluation Report on Internal Control for the Year 2025

Announcement on Changes in Accounting Policies

Announcement on the Provision for Asset Impairment for the Year 2025

Special Report on the Management and Use of Raised Funds for the Year 2025

Zhongshan Securities Co., Ltd. on the Verification Opinion Regarding Jiangxi Tonghe Pharmaceutical Co., Ltd. Using Part of the Idle Raised Funds to Temporarily Supplement Working Capital

Announcement on Using Part of the Idle Raised Funds to Temporarily Supplement Working Capital

Feasibility Analysis Report on Conducting Foreign Exchange Derivative Trading Business

Zhongshan Securities Co., Ltd. on the Verification Opinion Regarding Jiangxi Tonghe Pharmaceutical Co., Ltd. Conducting Foreign Exchange Derivative Trading Business

Announcement on Conducting Foreign Exchange Derivative Trading Business

Notice of the 2025 Annual Shareholders' Meeting

Announcement of Resolutions from the 7th Meeting of the 4th Board of Directors

Announcement on the Profit Distribution Plan for the Year 2025

Quarterly Report for Q1 2026

Verification Report on the Special Report of the Management and Use of Raised Funds for the Year 2025

Evaluation Report on the Performance of the Accounting Firm for the Year 2025

Report on the Audit Committee's Supervision of the Accounting Firm's Performance for the Year 2025

Special Report on Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Summary Table of Non-Operating Fund Occupation and Other Related Fund Transactions for the Year 2025

Special Opinion on the Independence of Independent Directors

Audit Report for the Year 2025

Annual Report for the Year 2025

Summary of the Annual Report for the Year 2025

Zhongshan Securities Co., Ltd. on the Verification Opinion Regarding Jiangxi Tonghe Pharmaceutical Co., Ltd. Using Idle Raised Funds for Cash Management

2026-015 Announcement on Using Temporarily Idle Raised Funds for Cash Management

Announcement on the Return of Temporarily Used Fundraising Funds for Supplementing Working Capital

Announcement on Obtaining Invention Patent Certificates

Announcement on the Company's API Passing CDE Approval